In this review, we aim to summarize the most relevant literature for hormonal therapy in endometrial cancer, including single-agent and combinations of progesterones, selective estrogen receptor modulators and degraders, aromatase inhibitors, as well as hormonal combinations with other targeted therapies. This evidence concerns the gene ESR1 and endometrial cancer.